Discontinued — last reported Q4 '25
Income Before Tax
Pre-Tax Income (Domestic)
Vertex Pharmaceuticals Pre-Tax Income (Domestic) remained flat by 0.0% to $705.30M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 306.0%, from -$342.43M to $705.30M. Over 2 years (FY 2023 to FY 2025), Pre-Tax Income (Domestic) shows relatively stable performance with a -4.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementIncome Statement
SectionIncome Before Tax
CategoryProfitability
SignalHigher is better
VolatilityStable
First reportedQ1 2015
Last reportedQ4 2025
How to read this metric
An increase suggests strong domestic market demand or operational efficiency within the home region.
Detailed definition
The portion of pre-tax earnings generated from operations within the company's home country. This metric provides insigh...
Peer comparison
Standard geographic breakdown provided by most multinational corporations.
Metric ID:
msft_income_before_tax_domesticHistorical Data
3 years
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $3.09B | -$1.37B | $2.82B |
| YoY Change | — | -144.3% | +306.0% |
Range-$1.37B – $3.09B
CAGR-4.4%
Avg YoY Growth+80.8%
Median YoY Growth+80.8%
Pre-Tax Income (Domestic) at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's pre-tax income (domestic)?
- Vertex Pharmaceuticals (VRTX) reported pre-tax income (domestic) of $705.30M in Q4 2025.
- How has Vertex Pharmaceuticals's pre-tax income (domestic) changed year-over-year?
- Vertex Pharmaceuticals's pre-tax income (domestic) increased by 306.0% year-over-year, from -$342.43M to $705.30M.
- What is the long-term trend for Vertex Pharmaceuticals's pre-tax income (domestic)?
- Over 2 years (2023 to 2025), Vertex Pharmaceuticals's pre-tax income (domestic) has grown at a -4.4% compound annual growth rate (CAGR), from $3.09B to $2.82B.
- What does pre-tax income (domestic) mean?
- Pre-tax profit earned specifically from domestic business operations.